Clinical Studies, Convertible Senior Notes, and Commercial Supply Contracts - Research Report on Gilead, Hologic, Regeneron, OPKO, and Unilife Editor Note: For more information about this release, please scroll to bottom PR Newswire NEW YORK, November 25, 2013 NEW YORK, November 25, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Gilead Sciences, Inc. (NASDAQ: GILD), Hologic, Inc. (NASDAQ: HOLX), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), OPKO Health Inc. (NYSE: OPK), and Unilife Corp. (NASDAQ: UNIS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Gilead Sciences, Inc. Research Report On November 18, 2013, Gilead Sciences, Inc. (Gilead) announced that its Phase 3 study (Study 116) evaluating idelalisib in combination with rituximab in previously-treated chronic lymphocytic leukemia (CLL) in patients who were not fit for chemotherapy was accepted for presentation during a late-breaking abstracts session at the Annual Meeting of American Society of Hematology (ASH) in New Orleans (Abstract #LBA-6). Gilead reported that Study 116 was stopped early based on a pre-specified interim analysis performed by an external Data Monitoring Committee (DMC) showing a highly statistically significant effect on the primary endpoint of progression-free survival. Gilead added that during the study, safety was in line with previous observations, and was consistent with advanced disease patients receiving CD20 antibody therapy. The Company informed that it will present detailed results from the study at ASH on December 10, 2013. The Full Research Report on Gilead Sciences, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/9898_GILD -- Hologic, Inc. Research Report On November 14, 2013, Hologic, Inc. (Hologic) announced that holders of the 2.00% Convertible Senior Notes due 2037 (CUSIP No. 436440 AA9) issued December 10, 2007 (the Notes) have the right to surrender their Notes for repurchase by the Company pursuant to their option (the Put Option) under the Indenture governing the Notes, dated as of December 10, 2007 (the Base Indenture) as supplemented by the First Supplemental Indenture, dated as of December 10, 2007 (the Supplemental Indenture and together with the Base Indenture, the Indenture). The Company added that with the Put Option, each holder of the Notes can require the Company to repurchase all or any part (in principal amount equal to $1,000 or integral multiples thereof) of such holder's Notes on December 13, 2013 (the Put Option Repurchase Date) at a repurchase price (the Put Option Repurchase Price) equal to 100% of the principal amount of the Notes, plus accrued and unpaid interest to, but not including, the Put Option Repurchase Date, upon the terms and subject to the conditions set forth in the Indenture and the Notes. Hologic further informed that the holders of Notes may exercise Put Option starting 9:00 a.m. New York City Time on the date of the announcement until 5:00 p.m. New York City Time on December 12, 2013. The Full Research Report on Hologic, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/d132_HOLX -- Regeneron Pharmaceuticals Inc. Research Report On November 20, 2013, Regeneron Pharmaceuticals Inc.'s stock rose 0.33%, ending the day at $274.68. Over the previous three trading sessions, shares of Regeneron declined 1.90% compared to the Nasdaq Composite which declined 1.62% during the same period. The Full Research Report on Regeneron Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/8ea7_REGN -- OPKO Health Inc. Research Report On November 15, 2013, OPKO Health Inc. (OPKO) has completed patient recruitment in the first phase 3 trial of Rayaldy to treat patients with secondary hyperparathyroidism (SHPT), stage 3 or 4 kidney (CKD) and vitamin D insufficiency. According to the Company, this trial is the first of two identical randomized, double-blind, placebo-controlled, multi-site studies intended to establish the safety and efficacy of Rayaldy as a new treatment for SHPT in the targeted population. OPKO added that the endpoints of both studies (being conducted in parallel), include vitamin D status and changes in serum calcium, serum phosphorus, and plasma intact parathyroid hormone. OPKO informed that top-line data from both trials are expected in mid-2014. The Full Research Report on OPKO Health Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/cd43_OPK -- Unilife Corp. Research Report On November 20, 2013, Unilife Corp. (Unilife) announced that it has signed a long-term commercial supply contract with Hikma Pharmaceuticals PLC (Hikma) for the use of Unifill prefilled syringes with a range of generic injectable drugs. Unilife reported that it will supply Hikma with customized prefillable delivery systems from its Unifill platform, including the Unifill syringe and the Unifill Nexus under the 15-year global agreement. Unilife informed that it will begin product sales to Hikma in early 2014. Under the terms of the contract, Unilife stated that it will supply Hikma a minimum volume of 175MM units per year following a rapid high-volume ramp up period. In addition, Unilife confirmed that Hikma will pay Unilife $40 million in upfront and milestone payments, beginning with an initial upfront payment of $5 million immediately, and followed by an addition $15 million in payments expected during 2014. However, Unilife added that the final $20 million in milestone-based payments will be paid the following year. The Full Research Report on Unilife Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://www.analystscorner.com/r/full_research_report/cb4d_MSFT ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. AnalystsCorner.com SOURCE Analysts' Corner Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Clinical Studies, Convertible Senior Notes, and Commercial Supply Contracts - Research Report on Gilead, Hologic, Regeneron,
Press spacebar to pause and continue. Press esc to stop.